Your browser doesn't support javascript.
loading
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies.
Schaub, Stephanie K; Hartvigson, Pehr E; Lock, Michael I; Høyer, Morten; Brunner, Thomas B; Cardenes, Higinia R; Dawson, Laura A; Kim, Edward Y; Mayr, Nina A; Lo, Simon S; Apisarnthanarax, Smith.
Afiliación
  • Schaub SK; 1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
  • Hartvigson PE; 1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
  • Lock MI; 2 Department of Radiation Oncology, University of Western Ontario, London, Canada.
  • Høyer M; 3 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark.
  • Brunner TB; 4 Klinik für Strahlentherapie, Universitätsklinikum Magdeburg, Magdeburg, Germany.
  • Cardenes HR; 5 Department of Radiation Oncology, Stich Radiation Center, NY, USA.
  • Dawson LA; 6 Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Kim EY; 1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
  • Mayr NA; 1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
  • Lo SS; 1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
  • Apisarnthanarax S; 1 Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
Technol Cancer Res Treat ; 17: 1533033818790217, 2018 01 01.
Article en En | MEDLINE | ID: mdl-30068240
Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose-response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Technol Cancer Res Treat Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Technol Cancer Res Treat Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos